Product Information
SYMBRAVO 20-10 MG TABLET is a brand product labeled by Axsome Therapeutics, Inc., priced at $122.6431 per EA under NDC 81968002009. Its NADAC has been published 50 times since Oct 22, 2025.
FDA first approved this application on Jan 30, 2025.
Strength
20; 10 mg/1; mg/1
Manufacturer
Axsome Therapeutics, Inc.NDC
81968002009
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MELOXICAM; RIZATRIPTAN BENZOATEApproval Type
New Drug (NDA)
FDA Application
NDA215431FDA Approved
1/30/2025
On Market Since
5/19/2025
Pharmacological Classes
Price Statistics
The NADAC for SYMBRAVO 20-10 MG TABLET has been published 50 times since Oct 22, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $122.6431 per EA |
|---|---|
| All-time high | $122.8814 (Dec 10, 2025) |
| All-time low | $122.6431 (Sep 23, 2026) |
| 52-week high | $122.8814 |
| 52-week low | $122.6431 |
| Median price | $122.6975 |
| Average price | $122.7193 |
| Largest weekly change | -0.2% (Dec 17, 2025) |
| Weeks tracked | 50 |
| Tracking since | Oct 22, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the meloxicam, rizatriptan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Axsome Therapeutics, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
meloxicam, rizatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SYMBRAVO 20-10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SYMBRAVO 20-10 MG TABLET, manufactured by Axsome Therapeutics, Inc., is $122.6431 per EA (NDC 81968002009), effective Sep 30, 2026.
How has the price of SYMBRAVO 20-10 MG TABLET changed over time?
Over the history we have for it, the NADAC for SYMBRAVO 20-10 MG TABLET has held within roughly two percent of its current level. It has been tracked across 50 weekly CMS publications since Oct 22, 2025.
What are the highest and lowest recorded NADAC prices for SYMBRAVO 20-10 MG TABLET?
Since Oct 22, 2025, the NADAC for SYMBRAVO 20-10 MG TABLET has ranged from a low of $122.6431 (Sep 23, 2026) to a high of $122.8814 (Dec 10, 2025), with a median of $122.6975 per EA.
Are there cheaper alternatives to SYMBRAVO 20-10 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SYMBRAVO 20-10 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SYMBRAVO 20-10 MG TABLET?
SYMBRAVO 20-10 MG TABLET (NDC 81968002009) is labeled by Axsome Therapeutics, Inc., and CMS classifies it as a brand product.